CORBrief
All briefings

Daily Functional Health Briefing

Functional-health briefings written for the patient and seeker.

Evidence-Graded Brief: Vestibular Rehab, Microglial Metabolism and Unverified K2/D3 Claims

November 16, 2026

[Evidence notice: Secondary reporting or unverified claim; primary evidence has not been confirmed. Precise figures remain unverified.] According to Colton Clayton, AuD (Mayo Clinic Aging Forward podcast, expert opinion), vestibular rehabilitation is first-line when a vestibular deficit is identified, and prolonged vestibular suppressants should be avoided. Dr. David Perlmutter (Ben Greenfield Life, secondhand and unverified) argues that metabolic state governs microglial polarization and that anti-amyloid drugs showed little clinical benefit in a Cochrane analysis. Several widely circulated supplement claims (K2+D3 plaque regression, GLP-1 hair-loss protocols) came from Dr. Eric Berg's channel without identifiable primary data. [Provided source catalog: Provided links are not claim verification. Mayo Clinic — https://www.youtube.com/watch?v=WHTVSnt0Jkk; Ben Greenfield Life — https://www.youtube.com/watch?v=pq_sSzU4K24; Mayo Clinic — https://www.youtube.com/watch?v=gjjPurUXygY; Dr. Eric Berg DC — https://www.youtube.com/watch?v=zd4ZCemosNY; Dr. Eric Berg DC — https://www.youtube.com/watch?v=2Iqzuf1pqEw; Mayo Clinic — https://www.youtube.com/watch?v=ZtL74IHkqFc; Stanford Online — https://www.youtube.com/watch?v=OT2vep4lYJs; Dr. Suneel Dhand — https://www.youtube.com/watch?v=zf4wHytgGCw; Mayo Clinic — https://www.youtube.com/watch?v=ID4eHy0qZIY; Dr. Eric Berg DC — https://www.youtube.com/watch?v=btEXVPwHJ2A; moonshots_clips — https://www.youtube.com/watch?v=3CqBarJkLE0; MIT OpenCourseWare — https://www.youtube.com/watch?v=ApjChL4yFZs; MIT OpenCourseWare — https://www.youtube.com/watch?v=P1rIQBsZK90; MIT OpenCourseWare — https://www.youtube.com/watch?v=L1ZXvrjcYTs; MIT OpenCourseWare — https://www.youtube.com/watch?v=PFk0kDBNqY0]

Key takeaways

  • [Evidence notice: Secondary reporting or unverified claim; primary evidence has not been confirmed. Precise figures remain unverified.] Per Colton Clayton, AuD (Mayo Clinic, expert opinion), prioritize VRT for identified vestibular deficits and canal-specific maneuvers for BPPV, and limit meclizine/OTC suppressants to short-term use; his 80-90% success and 30%/60% recurrence figures are unreferenced.
  • [Evidence notice: Secondary reporting or unverified claim; primary evidence has not been confirmed. Precise figures remain unverified.] Perlmutter's immunometabolism framework (podcast, secondhand data) supports early measurement of fasting glucose, fasting insulin, HbA1c and waist/hip, but his 70% lifestyle-trial result was small and incompletely described.
  • [Evidence notice: Secondary reporting or unverified claim; primary evidence has not been confirmed. Precise figures remain unverified.] Do not quote the K2+D3 figures (21%, 24.5%, 71.6%) to patients: the trials were never identified. Screen for warfarin use and check 25-OH-D and calcium before any 10,000 IU/day D3 use.
  • [Evidence notice: Secondary reporting or unverified claim; primary evidence has not been confirmed. Precise figures remain unverified.] For GLP-1 RA hair shedding, order objective labs and assess protein and caloric intake before empiric betaine HCl, NAC or lysine; the video cited no data for any of them.

SECTION 1: KEY CLINICAL TAKEAWAYS

[Evidence notice: Secondary reporting or unverified claim; primary evidence has not been confirmed. Precise figures remain unverified.] - **Dizziness:** Per Colton Clayton, AuD, on Mayo Clinic's Aging Forward podcast (expert opinion, no trial cited), vestibular rehabilitation therapy (VRT) is first-line when a vestibular deficit is identified, and BPPV is treated with a canal-specific repositioning maneuver. His unreferenced estimates were 80-90% BPPV treatment success and about 30% recurrence at 1 year. He cautioned against prolonged meclizine or OTC suppressant use. - **Neurodegeneration risk:** According to Dr. David Perlmutter (podcast interview; claims not independently verified), fasting glucose, fasting insulin, HbA1c and waist/hip circumference are practical surrogates for metabolic-immune risk. His cited lifestyle trial (20 weeks, 70% stabilized or improved, small, details not given) should complement standard care, not replace it. - **K2+D3 for coronary calcification:** Dr. Berg's video cited 2 unnamed RCTs (21% and 24.5% plaque reduction; 71.6% fewer adverse events). No trial was identified, so these figures should not be quoted to patients. The source summary flags the 10,000 IU/day D3 dose as above the commonly cited 4,000 IU/day upper intake, and flags the warfarin-K2 interaction. - **Hair shedding on GLP-1 receptor agonists (RAs):** The source summary's clinician commentary favors an objective workup (CBC, ferritin, transferrin saturation, zinc, B12, TSH, protein adequacy) over empiric betaine HCl. Betaine HCl was advocated in the video without supporting data.

SECTION 2: NEW RESEARCH & BIOMARKERS

[Evidence notice: Secondary reporting or unverified claim; primary evidence has not been confirmed. Precise figures remain unverified.] **Clinical Bottom Line:** Perlmutter reports that a Cochrane analysis found anti-amyloid drugs 'essentially ineffective' on clinical outcomes, a secondhand claim that should be checked against the primary review before it informs counseling. - **Study Design:** Podcast interview. Studies are relayed from memory, and many lack sample sizes, effect estimates or endpoint definitions. - **Key Findings (as relayed):** - Cochrane meta-analysis: 17 studies, >20,000 participants, about 18 months each. Perlmutter reports about 25% of treated patients had hemorrhage, swelling or death. The source summary notes this appears higher than commonly reported ARIA rates and should be verified. - A BMJ Neurology 3-year extension reportedly showed steeper decline after amyloid removal, with no numbers given. - Ornish/Tanzi lifestyle trial: 20 weeks of diet, exercise, meditation and stress management in Alzheimer's/MCI patients. 70% stabilized or improved. Perlmutter himself calls these 'very small studies'. - Lixisenatide in Parkinson's (NEJM, April 2024, per Perlmutter): RCT with >100 participants for about 1 year on UPDRS. GI adverse events were about 40% vs 8% on placebo, and about 20% had vomiting. - EVOKE/EVOKE+ (oral semaglutide, Alzheimer's) missed clinical endpoints. A roughly 30% C-reactive protein reduction is a surrogate signal only. - Ultra-processed food: a 12.7-year observational study is associated with 13% higher Alzheimer's risk per daily serving and nearly 3-fold at ≥10 servings/day. Confounding is possible. - **Clinical Application:** Perlmutter proposes fasting glucose/insulin, HbA1c, waist/hip, uric acid, plasma p-tau217 and GFAP as surrogates, since microglial polarization (M1/M2) cannot be sampled in living humans. Gut assessment options he named were Genova CDSA 2.0 (calprotectin), Cyrex LPS antibodies and lactulose/mannitol permeability. TSPO PET shows microglial activation but is research-only and not specific to M1. **B. Exercise and colon cancer outcomes (Dr. Andrea Cheville, Mayo Clinic Cancer Conversations)** **Clinical Bottom Line:** According to Dr. Cheville, a colon cancer study in NEJM (2025) showed cancer-free survival improved by over 25% with consistent exercise, but no design details or confidence intervals were given. - **Study Design:** Verbal citation in a community webinar. The source summary suggests it may be the CHALLENGE trial, and the figure is likely a relative reduction, not an absolute one. - **Clinical Application:** Counsel graded, enjoyable activity (walking, gardening, dancing). Avoid quoting 25% as an absolute benefit until the primary paper is verified. **C. Cardiometabolic biomarkers (Dr. Suneel Dhand panel; Dr. Berg live Q&A)** **Clinical Bottom Line:** Panel and host opinion supports adding fasting insulin/HOMA-IR, urine albumin, ApoB, Lp(a) and hs-CRP to risk assessment, but neither source supplied lead-time or outcome data. - Dr. Sunil said HOMA-IR can detect insulin resistance 'a decade or more' before HbA1c rises. The source summary notes that this is unsupported and that cutoffs are not standardized. - Dr. Berg cites CAC scoring and fasting insulin <5 as better risk markers than LDL. The summary notes that <5 is not a guideline threshold and that a CAC of zero does not exclude soft plaque. - A caller's rebound in total cholesterol after statin cessation (about 117 on treatment, about 285, then about 240) is expected pharmacology, per the summary's analyst note, not evidence of physiologic 'need'. - All panelists endorsed statins for secondary prevention. The panel called primary-prevention data 'incredibly weak'. The summary notes that Cholesterol Treatment Trialists' meta-analyses show consistent relative risk reductions, with small absolute benefit in low-risk patients. **D. GLP-1 RA hair loss reporting (Dr. Berg channel)** **Clinical Bottom Line:** The speaker cites hair loss in about 3% on the label vs 37-68% in surveys, but gives no sources, so true incidence is unquantified. - Telogen effluvium from rapid weight loss is the most parsimonious explanation per the summary. A drug-specific effect is plausible but unproven. - **Clinical Application:** Evaluate for iron deficiency, B12 and zinc status, thyroid dysfunction and protein/caloric adequacy. Telogen effluvium usually appears 2-4 months after the trigger (summary's outside context). **E. Stereoelectroencephalography (sEEG) practice patterns (Kai, Mayo Clinic, STEIN Fireside Podcast)** **Clinical Bottom Line:** In this single-surgeon expert opinion, sEEG is reserved for discordant MRI/scalp EEG/semiology data and defines resection, ablation or neuromodulation targets. - Concordant cases skip sEEG and go to definitive therapy. - Targeting accuracy is about 1-2 mm. Electrode diameter is 0.8 mm vs a DBS cannula of about 1.6-1.7 mm. A typical implant is 15-18 leads with 200-250 contacts. - The speaker estimates post-resection seizure freedom at about 50-80% depending on center (unsourced). - Radiofrequency ablation (RFA) lesions are about 3 mm, with benefit usually transient. Test stimulation runs up to 24 hours (130 Hz, 30 Hz or cycling), and IED suppression is a surrogate not validated for long-term outcome. - Thalamic targets and brain-stimulation evoked potential mapping are institution-specific and not prospectively validated. - **Clinical Application:** Refer epilepsy patients with discordant data to a comprehensive center. Counsel that seizure freedom is not guaranteed and that backup stimulation is planned in advance.

SECTION 3: THERAPEUTIC MODALITIES & PROTOCOLS

[Evidence notice: Secondary reporting or unverified claim; primary evidence has not been confirmed. Precise figures remain unverified.] **Clinical Bottom Line:** VRT is described as first-line for stable vestibular hypofunction or age-related imbalance, with repositioning maneuvers for BPPV (expert opinion, no effect sizes). - **Mechanism of Action:** Adaptation (recalibrating vestibulo-ocular computations via cerebellar input), habituation (graded exposure reduces the mismatch threat response) and substitution (up-weighting vision and somatosensation). Epley moves displaced otoconia out of the posterior canal. Other canals need different maneuvers. - **Dosage, Administration & Safety:** - Often only a few PT visits, then a home program. - Start with seated head turns. Progress to hallway walking with head turns while reciting numbers. - Adjuncts: tai chi, strength training at least 2 days/week, dual-task practice (no studies cited). - BPPV: 80-90% success per Clayton, typically in 1-2 visits. Recurrence is about 30% at 1 year and about 60% at 5 years (unreferenced). - Relative contraindication: unstable, fluctuating inner-ear conditions. Stabilize first. - Meclizine and OTC Dramamine/Bonine are for short-term use only. - The summary adds that these are sedating anticholinergics with fall risk in older adults, and that central and red-flag causes need independent screening. - **Clinical Pearls:** Confirm with a positional test and re-test after the maneuver. If a home Epley fails, re-evaluate for a non-posterior canal. Frame recurrence as 'another incident', not treatment failure. **2. Metabolic and environmental neuroprotection (Perlmutter)** **Clinical Bottom Line:** Perlmutter's low-harm lifestyle package (exercise, fewer ultra-processed foods, gradual fiber increase, cleaner air) is supported by mechanistic and observational reasoning, not trials of disease reversal. - **Mechanism of Action:** Mitochondrial dysfunction and glycolytic shift push microglia toward M1. Gut-derived LPS and cytokines cross the BBB. PM2.5 reaches the brain via the cribriform plate. M1/M2 is acknowledged as a simplification. - **Dosage, Administration & Safety:** - Ancestral fiber intake of about 100 g/day (Perlmutter) and a study of about 100-130 g/day beating metformin on glycemic control (Greenfield, unidentified). Both advise gradual escalation. - HEPA-14 purifiers, cabin filter changes about every 6 months, N95 in high-AQI settings. - Ketone supplements, CoQ10 and urolithin A were mentioned with no doses or evidence. - Not endorsed: minocycline for prevention (microbiome disruption), BPC-157/TB-500 (Greenfield anecdote), and self-prescribed GLP-1 RAs for neuroprotection. - **Clinical Pearls:** Use the cardiovascular prevention analogy. Do not promise reversal. Discuss anti-amyloid decisions with primary data. **3. K2 + D3 + magnesium for coronary calcification (Dr. Berg with Dr. Philip Ovadia)** **Clinical Bottom Line:** The protocol rests on unreferenced trial claims (grade D) and should be framed to patients as investigational. - **Mechanism of Action:** K2 activates a carboxylation-dependent protein that directs calcium away from arteries (the host did not name matrix Gla protein). D3 is said to raise endothelial nitric oxide. Ovadia attributes endothelial injury to insulin resistance. The summary notes that his claim 'cholesterol cannot cross an intact endothelium' is contested. - **Dosage, Administration & Safety:** - Host protocol: D3 10,000 IU (frequency not stated), K2 100 mcg per 10,000 IU (MK-7 preferred), magnesium glycinate (no dose), low-carbohydrate diet, fasting insulin <5. - Per the summary: K2 antagonizes warfarin, and 10,000 IU exceeds the 4,000 IU upper intake. Check 25-OH-D and calcium, with caution in CKD, sarcoidosis, hyperparathyroidism and nephrolithiasis. - Monitor patients on insulin or sulfonylureas for hypoglycemia, and patients on SGLT2 inhibitors for euglycemic ketoacidosis. - Do not stop statins on this basis. CAC regression is not an established surrogate for event reduction. **4. GLP-1 RA hair-loss self-care (Dr. Berg channel; no data)** - **Dosage, Administration & Safety (as advocated):** betaine HCl 'two capsules or so' before meals, at least 3 eggs/day, NAC about 600 mg, L-lysine 500-1,000 mg, and 4 minutes of scalp massage with rosemary oil. No trial data were provided. - **Safety (summary's commentary):** betaine HCl is contraindicated in ulcer disease and gastritis and with NSAIDs or acid suppressants. NAC may potentiate nitroglycerin. L-lysine needs caution in renal impairment. - **Clinical Pearl:** The 'club root' on a shed hair is normal telogen morphology and does not diagnose a deficiency. **5. Additional items from the Dr. Berg Live Q&A (November 13, 2026; expert opinion, grade D)** - Selenium in Hashimoto's: the summary's analyst note cites about 200 µg/day with reduced TPO antibodies in meta-analyses, and avoidance above about 400 µg/day. Clinical outcome benefit is inconsistent. - TUDCA 2 capsules AM and 2 PM for gallbladder sludge. No trial data were cited, and ox bile is contraindicated in active ulcer. - Curcumin with piperine: about 2,000% absorption increase (small human study per the summary). Piperine inhibits CYP3A4/P-glycoprotein, so check drug interactions. - A caller with suspected stage IV endometrial stromal sarcoma asked about forgoing chemotherapy. The summary stresses urgent sarcoma-center referral. Ketogenic diet, fasting, ivermectin and mebendazole have no cited outcome data in this setting.

SECTION 4: PRACTICE IMPLEMENTATION & PEARLS

[Evidence notice: Secondary reporting or unverified claim; primary evidence has not been confirmed. Precise figures remain unverified.] Standardized home BP technique, patient-agenda-first visits and neutral inquiry about AI use are the lowest-effort changes supported by this set of sources, though all come from expert opinion. - **Home BP monitoring (Dr. Yvonne Commodore-Mensah, Mayo Clinic Health Matters, no data):** - Use a validated device with the correct cuff size. Measure before caffeine, food or smoking, after emptying the bladder. Sit 3-5 minutes and take 2 readings about 1 minute apart. - She cited a stated goal of <130/80 and sodium <2,000 mg/day, noting some canned soups exceed 1,000 mg per can. She said nearly 50% of US adults (about 120 million) have hypertension. - She suggested monthly visits until goal, then every 3-6 months, and favors two-drug single-pill combinations (evidence not named). - Her proposal of 3 consecutive days/month is simpler than the roughly 7-day protocols commonly used, so confirm against ACC/AHA guidance. - Report side effects rather than stopping drugs silently. - **Visit structure (Dhand panel, opinion):** Open with 'What's bothering you?', match labs to the complaint, and distinguish primary from secondary statin prevention. For falls, review orthostatic vitals, neuropathy, vision and medications, and advise against solo ladder use. The panel called the flu shot 'a total lie'. The summary notes that effectiveness is commonly 40-60% in well-matched seasons, with benefit on hospitalization in high-risk groups, so individualize the discussion. - **Patient AI use (Ashley Alexander, OpenAI, Stanford Healthcare AI podcast; vendor self-report):** She reported over 300 million people asking health questions weekly, with about 7 in 10 conversations outside clinic hours. A host cited a Pew survey in which about one-third used a chatbot for health. She said ChatGPT for clinicians is free to NPI-verified clinicians. No accuracy, hallucination or safety data were presented. Ask patients neutrally what they have used, and verify medication and triage advice. - **Rural oncology logistics (Cheville, Mayo Cancer Conversations):** She described mailed stool DNA tests, mobile mammography, oral agents, shorter radiation courses and local rehabilitation partnerships as capabilities, not outcome data. Reassess low-dose CT eligibility, since limited past smoking can qualify. One survivor reported increasing intake from about 2,000 to about 5,000 kcal/day during feeding-tube dependence (individual, anecdotal), supporting early dietitian reassessment. - **Non-clinical items:** In a technology podcast (Moonshots), Peter Diamandis said GLP-1 drugs are 'slowing aging by 9%', and Chamath Palihapitiya projected healthcare costs could halve. Neither was sourced, so neither should be shared with patients as established. Three MIT OpenCourseWare lectures (Prof. Juejun Hu) on amorphous materials, optical properties and glass fracture contain no clinical content, and no practice application is supported.

Get Functional Health briefings every weekday

Free email signup, with post angles tuned to your beat available on the Studio plan.

Get free briefings

Recent Functional Health briefings